Yatai Pharma announced that a total of 27 of its products have been included in the National Essential Medicines List 2026 edition, with five new additions and one removal. The newly added products are cefixime capsules, azithromycin for injection, acyclovir for injection, febuxostat tablets, and esomeprazole sodium for injection, while the removed product is clarithromycin capsules. The company expects this adjustment to have a positive impact on subsequent market expansion, driving broader coverage of the relevant products in the primary healthcare market and enhancing market competitiveness.
Zhejiang Yatai Pharmaceutical Co LtdFive products newly added to National Essential Medicines List, expected to expand market coverage and boost sales.